Biophytis and Blanver Collaborate to Develop BIO101 for Treating Multiple Indications
Shots:
- Biophytis and Blanver have entered into an exclusive license agreement to develop and commercialize BIO101 (20-Hydroxyecdysone) across LATAM incl. Brazil, Mexico, Argentina & Colombia
- The agreement provides Blanver with the rights to register, market & commercialize BIO101 for treating obesity, respiratory infections due to Covid-19, sarcopenia & Duchenne Muscular Dystrophy (DMD) post study completion
- Biophytis is entitled to receive upfront and additional milestones, making it an aggregate of ~$115M, plus double-digit net-sales-based royalties
Ref: Biophytis | Image: Biophytis
Related News:- Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
